Core Viewpoint - China Biopharmaceutical announced the latest results of a Phase III clinical study comparing Bemesumab injection combined with Anlotinib capsules to Pembrolizumab injection for first-line treatment of PD-L1 positive advanced non-small cell lung cancer (NSCLC), achieving the primary endpoint of progression-free survival (PFS) [1][2]. Group 1: Clinical Study Results - The CAMPASS study included 531 PD-L1 positive (TPS≥1%) patients with locally advanced (IIIB/C) or recurrent/metastatic NSCLC, randomized in a 2:1 ratio to receive either Bemesumab combined with Anlotinib or Pembrolizumab combined with placebo [1]. - In the overall population, the median PFS for the Bemesumab and Anlotinib group was 11.0 months, an increase of 3.9 months compared to the Pembrolizumab group (7.1 months), with a 30% reduction in the risk of disease progression/death (HR=0.70) [2]. - In the subgroup with TPS≥50%, the median PFS for the Bemesumab and Anlotinib group was extended by 6.1 months compared to the Pembrolizumab group, with a 40% reduction in the risk of disease progression/death (HR=0.60) [2]. Group 2: Safety and Tolerability - The common treatment-related adverse events in the Bemesumab and Anlotinib group were consistent with those seen in multi-targeted anti-angiogenic tyrosine kinase inhibitors (TKIs) or immunotherapy, with no new safety signals observed [3]. - Despite the extended median treatment duration due to efficacy advantages, tolerability was not significantly affected, with the rate of treatment discontinuation due to adverse events being 7.1%, lower than the Pembrolizumab group (8.0%) [3]. - The study is the first global Phase III clinical trial of an anti-PD-L1 monoclonal antibody combined with multi-targeted anti-angiogenic TKI for first-line treatment of PD-L1 positive advanced NSCLC, highlighting its significant clinical value [3].